Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Dexa Medica Group

Clinicaltrial registered16 Nov 2026

Dexa Medica Group

16 Nov 2026: Trial registered · Bioequivalence Study of Sitagliptin/Metformin 50 mg/1000 mg Extended Release Tablet. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
16 Nov 2026
Title
Bioequivalence Study of Sitagliptin/Metformin 50 mg/1000 mg Extended Release Tablet
Conditions
Healthy Volunteers
Phase
Not applicable
Study Type
Interventional
Status
Completed
Countries
Indonesia
Country
Indonesia
Reference
NCT07937436
Location
Indonesia
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Dexa Medica Group

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

Across AOS Research

Other records for Dexa Medica Group in our registers.

More from Indonesia

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.